Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

This study is ongoing, but not recruiting participants.

Study NCT00363883 Information provided by California Cancer Consortium

First Received: August 10, 2006 Last Updated: October 11, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

Publications:

Cheung EM, Quinn DI, Tsao-Wei DD, et al.: Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy--California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. [Abstract] J Clin Oncol 26 (Suppl 15): A-16058.